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OBJECTIVE — Both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT)
have been linked to systemic inﬂammation in nondiabetic cohorts. We examined the relation-
ships between VAT and SAT and systemic inﬂammatory markers in a large well-characterized
cohort of subjects with type 2 diabetes.
RESEARCH DESIGN AND METHODS — Three hundred eighty-two subjects with
type 2 diabetes in the CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using
Pioglitazone) study cohort underwent abdominal computed tomography to determine SAT and
VAT distribution. Fasting blood was obtained for measurement of inﬂammatory markers. The
relationships between inﬂammatory markers and BMI, SAT, and VAT were examined using
regressionmodelsadjustedforage,sex,diabetestreatment,durationofdiabetes,smoking,statin
use, and A1C.
RESULTS — VAT was positively related to CRP, monocyte chemoattractant protein (MCP),
intracellular adhesion molecule (ICAM)-1, and plasminogen activator inhibitor type 1 (PAI-1)
antigenbeforeadjustmentforBMI.AfteradjustmentforBMI,therelationshiptoCRPwaslostbut
positive associations with MCP (P  0.01), PAI-1 (P  0.0001), ICAM-1 (P  0.01), and
vascularcelladhesionmolecule(P0.01)wereevident.BMIwaspositivelyrelatedtoCRP(P
0.0001) and IL-6 (P  0.01) even after adjustment for VAT and SAT. SAT was not related to any
inﬂammatory marker after adjustment for BMI.
CONCLUSIONS — In this large group of subjects with type 2 diabetes, BMI was most
strongly associated with CRP and IL-6 levels. SAT was not associated with markers of systemic
inﬂammation. The size of the VAT depot provided information additional to that provided by
BMI regarding inﬂammatory markers that are strongly related to vascular wall remodeling and
coagulation. Our ﬁndings suggest that adipose tissue distribution remains an important deter-
minant of systemic inﬂammation in type 2 diabetes.
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O
besity, especially of the abdominal
type,isassociatedwithaproinﬂam-
matory state. The association be-
tween obesity and inﬂammation was ﬁrst
reported by Hotamisligil et al. (1), who
demonstrated expression of tumor necro-
sis factor- (TNF-) in adipose tissue, an
increase in its expression in obesity, and
its ability to induce insulin resistance.
Since this report, adipose tissue has been
recognized as an important source of a
number of hormones and cytokines, in-
cluding TNF-, interleukin (IL)-6, and
monocyte chemoattractant protein
(MCP)-1 (2). While adipokines such as
leptin and adiponectin are exclusively
produced by adipocytes, inﬂammatory
cytokines can be produced by both adi-
pocytes and adipose tissue macrophages
(ATMs) (2). Obesity is associated with an
increase in ATM inﬁltration (3) and acti-
vation (4). Epidemiological studies have
demonstratedanincreaseinplasmalevels
of inﬂammatory markers such as C-reac-
tive protein (CRP), IL-6, and TNF- in
obesity and a strong association with
these levels and risk for type 2 diabetes
and cardiovascular disease (2,5). Weight
loss in humans has been associated with a
reductioninATMinﬁltrationandlevelsof
systemic inﬂammatory markers (6).
There is also evidence that adipose tissue
isolated from speciﬁc fat depots, such as
visceral fat, may express higher levels of
inﬂammatory markers such as IL-6 (7),
MCP-1(8),andplasminogenactivatorin-
hibitor type 1 (PAI-1) (9).
For this report, we examined the as-
sociation between abdominal fat com-
partments measured by computed
tomography (CT) and markers of sys-
temic inﬂammation in 382 subjects with
type 2 diabetes who participated in the
Carotid Intima-Media Thickness in
Atherosclerosis Using Pioglitazone
(CHICAGO) study (10). To our knowl-
edge, this is the largest cohort in which
the relationship between adipose tissue
distribution (using abdominal CT) and
inﬂammation in subjects with type 2 dia-
betes has been examined. A recent study
of mostly non-Hispanic whites with low
prevalence of diabetes and cardiovascular
disease showed that both visceral adipose
tissue (VAT) and subcutaneous adipose
tissue (SAT) are associated with inﬂam-
matory markers, though the association
for VAT was stronger (11). In this analy-
sis,wedeterminedwhetheradiposetissue
distribution and speciﬁc adipose tissue
depots remain important determinants of
systemic inﬂammation in type 2 diabetes.
RESEARCH DESIGN AND
METHODS— Subjectsforthecurrent
analysis were Caucasian and African-
American participants in the CHICAGO
trial, a prospective study of the effects of
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oncarotidintima-mediathicknessinsub-
jectswithtype2diabetes(10).Thedetails
of the study have been previously re-
ported (10). Data included in this report
were obtained before randomization to
treatment groups. The study was ap-
proved by central and local institutional
review board committees, and all partici-
pantsprovidedwritteninformedconsent.
All subjects underwent measurements of
height,weight,andwaistandhipcircum-
ference by a trained nurse at the baseline
visit. Waist circumference was measured
atthesmallestcircumferencebetweenthe
ribsandiliaccrest,andhipcircumference
was measured at maximum circumfer-
ence between the iliac crest and crotch to
the nearest 0.1 cm.
SubjectsunderwentanabdominalCT
scan for determination of VAT, SAT, and
totalabdominaladiposetissue(TAT).Ab-
dominal adipose tissue content and dis-
tribution were quantiﬁed by CT scan at
the level of L4–L5 vertebrae while the
subjects were in supine position with
both arms stretched above the head. A
single 6-mm slice was taken during sus-
pended respiration after a normal expira-
tion. TAT was measured by delineating
the body surface with a receiver operator
instrument and then by computing the
adipose tissue volume using an attenua-
tion range of 190 to 30 HU. VAT area
was quantiﬁed by delineating the abdom-
inal cavity at the internal aspect of the
abdominal wall and the posterior aspect
ofthevertebralbodywiththereceiverop-
erator instrument. SAT area was calcu-
lated by subtracting VAT from TAT
volume. To obtain VAT, SAT, and TAT
volumes, the area for each fat component
was multiplied by the slice thickness.
Fasting blood samples were obtained at
the baseline visit for measurement of in-
ﬂammatory markers and A1C. Inﬂamma-
tory markers were measured using kits
according to the manufacturer’s instruc-
tions: plasma CRP (Roche Diagnostics,
Indianapolis, IN), intracellular adhesion
molecule (ICAM)-1 and vascular cell ad-
hesion molecule (VCAM)-1 (R&D Sys-
tems, Minneapolis, MN), matrix
metalloproteinase (MMP)9 (R&D Sys-
tems),andPAI-1(TrinityBiotechUSA,St.
Louis, MO). Fibrinogen was measured by
direct coagulation analysis (Dade Behring
Marburg,Marburg,Germany),humanin-
sulin by ELISA (Linco, St. Charles, MO),
and A1C by high-performance liquid
chromatography (Bio-Rad, Hercules,
CA).IL-6wasmeasuredbyELISA(Quan-
tikine HS; R&D Systems).
Statistical methods
Log transformation of the data was per-
formed when it was necessary to achieve
homogeneity of variance. Sex differences in
inﬂammatory biomarkers, VAT, SAT, TAT,
and BMI were compared by ANCOVA ad-
justed for age, BMI, baseline diabetes treat-
ment, duration of diabetes, years of
smoking, statin use, and A1C.
Age- and sex-adjusted Pearson corre-
lation coefﬁcients were used to assess the
relationship between BMI, waist circum-
ference, A1C, SAT, VAT, TAT, and each
inﬂammatorymarker.Wealsoperformed
multivariable regression models adjusted
for age, sex, baseline diabetes treatment,
duration of diabetes, years of smoking,
statin use, and A1C to evaluate the rela-
tionship between each inﬂammatory
marker and SAT, VAT, and BMI. SAT,
VAT, and BMI were ﬁrst standardized to
mean 0 and SD 1. We calculated regres-
sion coefﬁcients quantifying the es-
timated change in log-transformed
biomarker per SD increase in SAT, VAT,
or BMI separately and then transformed
back to estimate the percent change in
each biomarker. The multivariable analy-
ses were repeated with addition of BMI to
the models when assessing the relation-
ship between VAT or SAT and inﬂamma-
tory markers or with the addition of both
VAT and SAT to the model when assess-
ing the relationship between BMI and in-
ﬂammatory markers. The associations
between VAT and inﬂammatory markers
were further examined by multivariable
models after addition of SAT, or of hip
circumference, to models that included
BMI. Similar analyses were performed to
evaluate the associations between SAT
and inﬂammatory markers before and af-
ter adjustment for BMI or for BMI and
VAT. To further examine the role of
smoking, we repeated all of the above
analyses by placing smoking as a categor-
icalvariableinsteadofyearsofsmokingas
follows: current smokers (n  58), ex-
smokers(n186),andnonsmokers(n
127). To evaluate whether the associa-
tions between abdominal fat depots and
inﬂammatory markers were related to the
degree of obesity, we repeated the above
analysesintwogroupsbasedonamedian
splitofBMI.Analyseswereperformedus-
ingthe11.0PCpackageofSPSSstatistical
software (SPSS, Chicago, IL). P  0.01
was considered signiﬁcant in order to ad-
just for evaluation of multiple inﬂamma-
tory markers for their relationship to VAT
(which was our primary analysis).
RESULTS— The baseline characteris-
tics of study subjects are presented in Ta-
ble 1. The mean age was 61 years. Thirty-
eight percent of subjects were women,
55% were on statin therapy, and 65%
were current or former smokers. Subjects
were on the following diabetes therapy at
the time of participation in the study:
15% were not taking any medications for
diabetes, 15% were taking sulfonylureas,
29% were taking metformin, 31% were
taking a combination of metformin and
sulfonylureas, and 10% were on insulin
therapy. The average  SD BMI was
32.5  5.1 kg/m
2, the mean duration of
type 2 diabetes was 92  86 months, and
the mean A1C was 7.4  0.9%. The me-
dian (interquartile range) CRP level was
2.7 mg/l (1.4–5.5), ICAM-1 was 241
ng/ml (196–294), MCP was 61 pg/ml
(43–61), VCAM-1 was 670 mg/dl (537–
816), ﬁbrinogen was 322 mg/dl (249–
391), MMP9 was 439 ng/ml (305–613),
PAI-1 was 29 ng/ml (20–43), and IL-6
was 2.49 pg/ml (1.8–3.8) (data not
shown).
Men had a higher amount of VAT
than women (P  0.0001), whereas
women had a higher amount of SAT than
men (P  0.0001) (Table 2). BMI and
Table 1—Baseline characteristics of study
participants
Age (years) 61  8
BMI (kg/m
2) 32.5  5.1
Waist circumference (cm) 108  13
Hip circumference (cm) 113  12
Duration of type 2 diabetes
(months) 92  86
A1C (%) 7.4  0.9
Smoking
Current 16
Former 49
Never 35
Diabetes therapy
None 15
Sulfonylurea 15
Metformin 29
Sulfonylurea and metformin 31
Insulin 10
Statin use
Statin 55
No statin 45
Sex
Men 62
Women 38
Data are means  SD or %. Study participants are
subjects with type 2 diabetes (n  382).
Sam and Associates
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women. CRP and ﬁbrinogen levels were
higher in women than men (P  0.0001)
(Table 2).
In age- and sex-adjusted correlations
(Table 3), VAT was positively associated
with CRP, ICAM-1, MCP, MMP9, and
PAI-1. BMI was positively associated with
CRP, ﬁbrinogen, PAI-1, and IL-6,
whereas SAT was positively associated
only with CRP (Table 3). TAT was posi-
tively associated with CRP, ICAM-1, and
PAI-1. Waist circumference was posi-
tively associated with CRP, ICAM-1,
MMP9, PAI-1, and IL-6 (Table 3). A1C
wasnotassociatedwithanyoftheinﬂam-
matory markers (Table 3).
Theresultsfrommultivariableregres-
sion models adjusted for age, sex, diabe-
tes treatment, duration of diabetes, A1C,
and smoking years are shown in Table 4.
The percent change in each inﬂammatory
marker per SD of adiposity measurement
is given for signiﬁcant associations. We
also adjusted for statin use, as these drugs
havebeenshowntoinﬂuencethelevelsof
circulating inﬂammatory markers (12).
After these adjustments, VAT remained
positively associated with CRP, ICAM-1,
MCP, and PAI-1 (Table 4). After addition
of BMI to the model, the association of
VAT with CRP was no longer evident;
however, VAT remained associated with
ICAM-1, MCP, and PAI-1, and a positive
association was observed between VAT
and VCAM-1 (Table 4). BMI was strongly
and positively associated with CRP and
IL-6, and the associations persisted after
adjustment for VAT and SAT (Table 4).
The relationship between CRP and BMI
was stronger in women (R
2  0.32; P 
0.001) than men (R
2  0.17; P  0.02)
even after adjustment for VAT and SAT
(data not shown). BMI was also positively
associated with ﬁbrinogen and MMP9;
however, the signiﬁcant association was
lost after adjustment for VAT and SAT
(Table 4). SAT was associated with CRP
and IL-6 but not after adjustment for BMI
(Table 4). Adjustment for smoking as a
categorical variable rather than years of
smoking did not alter any of these associ-
ations.Testsforheterogeneity(Caucasian
vs. African American) were not signiﬁ-
cantforanyoftheassociationsshownin
Table 4.
Even though SAT was not associated
withanyoftheinﬂammatorymarkers,we
testedwhetheritalteredtheassociationof
VAT with these markers. We added SAT
to the multivariable model analyzing the
relationshipbetweenVATandtheinﬂam-
matorymarkers,andthisadditiondidnot
modify the association between VAT and
any of the inﬂammatory markers (data
not shown). It has also been suggested
thatlower-bodySATmaymitigatethead-
verse inﬂuence of VAT on cardiometa-
bolic risk. We therefore added hip
circumference, as an index of lower-body
subcutaneous fat mass, to the multivari-
able model for the relationship between
VAT and inﬂammatory markers. The ad-
dition of hip circumference to the multi-
variable model also did not signiﬁcantly
alter the association between VAT and
any of the inﬂammatory markers (data
not shown).
As noted above, our results differ
from those reported in a large cohort of
predominantly nondiabetic and less
obese subjects (11). In order to gain in-
sight into whether this difference is re-
lated to the presence of diabetes or to
more pronounced obesity in our cohort,
the associations between adipose tissue
depots and inﬂammatory markers were
examined separately in two groups based
on a median split of BMI at 31.1 kg/m
2.
No independent associations between
SATandanyoftheinﬂammatorymarkers
wereobservedineitherBMIcategory.The
positive relationships between VAT and
PAI-1, MCP, ICAM-1, and VCAM-1 were
present in both BMI groups and were
stronger in the lower median split of BMI
(data not shown).
CONCLUSIONS — We found that
adipose tissue distribution is an impor-
tant determinant of systemic inﬂamma-
tion in a large, multiethnic population of
well-characterized subjects with type 2
diabetes. To our knowledge, this is the
largest cohort of subjects with type 2 dia-
betes who have undergone determination
of abdominal fat distribution by imaging
for analysis of its relationship to systemic
inﬂammation. VAT was positively associ-
ated with a number of inﬂammatory
markers even after adjustment for BMI.
BMI, independent of VAT and SAT, was
theprimarydeterminantofCRPandIL-6.
After adjustment for BMI, SAT was not
Table 2—Sex differences in inﬂammatory markers, BMI, VAT, SAT, and TAT in type 2
diabetes
Men Women P*
CRP (mg/l) 2.3 (1.3–4.3) 3.6 (1.6–9.7) 0.0001
ICAM-1 (ng/ml) 243 (202–294) 234 (179–301) 0.7
MCP (pg/ml) 62 (44–89) 60 (43–87) 0.8
VCAM-1 (mg/dl) 682 (545–834) 656 (525–807) 0.07
Fibrinogen (mg/dl) 306 (245–375) 357 (276–421) 0.0001
MMP9 (ng/ml) 451 (318–658) 392 (298–559) 0.4
PAI-1 (ng/ml) 28 (20–43) 30 (21–44) 0.1
IL-6 (pg/ml) 2.4 (1.8–3.6) 2.5 (1.8–4.1) 0.9
BMI (kg/m
2) 31.8 (28.4–35.2) 32.7 (28.6–38.4) 0.2
VAT (cm
3) 137 (105–180) 103 (80–131) 0.0001
SAT (cm
3) 175 (128–220) 220 (165–276) 0.0001
TAT (cm
3) 311 (245–395) 328 (249–397) 0.9
Data are medians (interquartile range 25th–75th percentiles). *ANCOVA for comparison between sexes
adjusted for age, BMI, diabetes therapy, duration of diabetes, years of smoking, statin use, and A1C.
Table 3—Age- and sex-adjusted Pearson correlation coefﬁcients between log-transformed
inﬂammatory markers and BMI, waist circumference, TAT, VAT, SAT, and A1C
BMI Waist TAT VAT SAT A1C
CRP 0.34* 0.26* 0.28* 0.18* 0.17* 0.003
ICAM-1 0.12 0.16* 0.17† 0.21* 0.08 0.02
MCP 0.05 0.03 0.06 0.16* 0.01 0.003
VCAM-1 0.04 0.05 0.02 0.10 0.04 0.02
Fibrinogen 0.16* 0.13 0.12 0.07 0.08 0.04
MMP9 0.13 0.18* 0.13 0.17* 0.04 0.03
PAI-1 0.14† 0.18* 0.18† 0.29* 0.05 0.04
IL-6 0.21* 0.19* 0.12 0.07 0.04 0.07
*P  0.001; †P  0.01.
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ers. Interestingly, adjusting for SAT (in-
dex of central SAT) or hip circumference
(index of peripheral SAT) did not reduce
the importance of VAT for predicting sys-
temic inﬂammatory markers. Our ﬁnd-
ings suggest that both BMI and VAT are
correlates of systemic inﬂammation in
obese subjects with type 2 diabetes. Fur-
thermore, VAT provides information ad-
ditional to BMI for a number of systemic
inﬂammatory markers that are strongly
associated with vascular remodeling and
coagulation (13–18).
An increase in inﬂammatory markers
has been associated with increased risk
for metabolic abnormalities and cardio-
vascular disease (2,5,19). Expansion of
adiposetissueexplainstheseassociations,
as it promotes a systemic inﬂammatory
response. Inﬂammatory molecules such
as TNF-, IL-6, serum amyloid A, and
MCP-1 are produced in signiﬁcant quan-
titybyATMsandadipocytes(2,5,19).Re-
cently, it has been shown that obesity is
associated with increased ATM inﬁltra-
tion (up to 40%) and a change in ATM
polarization to a more proinﬂammatory
state (3,4). Both SAT and VAT are known
to secrete inﬂammatory cytokines in vitro
and have been implicated in metabolic
disorders (7–9). Subcutaneous abdomi-
nalfatisdividedintosuperﬁcialanddeep
layers by a fascial plane, and recent evi-
dence suggests that there maybe meta-
bolic differences between the two
components (20). For example, deep but
not superﬁcial subcutaneous abdominal
tissuehasbeenassociatedwithperipheral
insulin resistance and features of meta-
bolic syndrome (20). We were not able to
separate these compartments in the cur-
rent study.
A recent study from the Framingham
cohort has shown that both VAT and SAT
are associated with CRP and a number of
other inﬂammatory markers, indepen-
dent of BMI; however, the associations
were stronger for VAT (11). Subjects in
the CHICAGO cohort were more obese
compared with the Framingham cohort,
and all had type 2 diabetes, whereas the
prevalence of type 2 diabetes in the Fra-
mingham cohort was 10% (11). There-
fore,whileourdataafﬁrmtheimportance
of adipose tissue distribution on inﬂam-
matory markers in obese subjects even af-
Table 4—Multivariable-adjusted linear regression models for relation of SAT, VAT, or BMI to inﬂammatory markers
Multivariable model*
Multivariable model with SAT or VAT adjusted for
BMI or with BMI adjusted for both SAT and VAT
R
2 P
Log difference  SE
per SD (% change†) R
2 P
Log difference  SE per
SD (% change†)
CRP (mg/l)
SAT 0.23 0.0001 0.148  0.026 (41†) 0.26 0.07 0.063  0.034
VAT 0.16 0.003 0.088  0.029 (22†) 0.24 0.9 0.003  0.031
BMI 0.24 0.0001 0.159  0.023 (44†) 0.26 0.001 0.132  0.039 (36†)
ICAM-1 (ng/ml)
SAT 0.09 0.05 0.025  0.013 0.09 0.7 0.007  0.017
VAT 0.09 0.001 0.046  0.013 (11†) 0.09 0.008 0.040  0.015 (10†)
BMI 0.06 0.03 0.025  0.011 0.10 0.5 0.014  0.019
MCP (pg/ml)
SAT 0.10 0.9 0.001  0.016 0.10 0.7 0.008  0.022
VAT 0.13 0.001 0.057  0.017 (14†) 0.11 0.001 0.061  0.019 (15†)
BMI 0.09 0.2 0.017  0.014 0.12 0.6 0.013  0.024
VCAM-1 (mg/ml)
SAT 0.07 0.5 0.007  0.01 0.07 0.8 0.003  0.013
VAT 0.07 0.3 0.010  0.011 0.09 0.01 0.027  0.011 (6†)
BMI 0.07 0.3 0.009  0.009 0.09 0.1 0.021  0.015
Fibrinogen (mg/dl)
SAT 0.14 0.02 0.018  0.008 0.15 0.5 0.008  0.011
VAT 0.12 0.2 0.011  0.009 0.13 0.8 0.001  0.01
BMI 0.13 0.003 0.022  0.007 (5†) 0.15 0.2 0.017  0.012
MMP9 (ng/ml)
SAT 0.14 0.1 0.021  0.013 0.15 0.9 0.002  0.018
VAT 0.14 0.03 0.033  0.015 0.15 0.2 0.020  0.017
BMI 0.14 0.01 0.031  0.012 (7†) 0.17 0.2 0.027  0.020
PAI-1 (ng/ml)
SAT 0.12 0.3 0.015  0.016 0.14 0.4 0.019  0.021
VAT 0.18 0.0001 0.074  0.017 (19†) 0.17 0.0001 0.055  0.017 (14†)
BMI 0.13 0.02 0.033  0.014 0.17 0.3 0.023  0.024
IL-6 (pg/ml)
SAT 0.16 0.001 0.058  0.017 (14†) 0.17 0.3 0.021  0.022
VAT 0.10 0.07 0.025  0.016 0.14 0.8 0.006  0.02
BMI 0.15 0.0001 0.069  0.015 (17†) 0.17 0.01 0.062  0.025 (15†)
*Multivariablemodelisadjustedforage,sex,diabetestherapy,durationofdiabetes,yearsofsmoking,statinuse,andA1C.†Percentchangeininﬂammatorymarkers
for every 1-SD increase in VAT, SAT, or BMI.
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that relationships between speciﬁc adi-
pose tissue depots and inﬂammatory
markers may be modiﬁed by the onset of
diabetes. Similar to previous studies, we
observed sex differences in CRP and ﬁ-
brinogen levels with higher levels in
women (21). We also found a stronger
association between CRP and BMI, inde-
pendent of VAT and SAT, in women.
In multivariable fully adjusted mod-
els, an increase in VAT was strongly asso-
ciated with an increase in PAI-1 levels
independent of BMI. A higher PAI-1
plasma level has been linked to a higher
risk of coronary heart disease in subjects
with type 2 diabetes (15). Both animal
and human studies suggest that PAI-1 ex-
pression is higher in VAT than SAT
(9,22). Our data support the strong asso-
ciationbetweenVATandPAI-1levels,in-
dependent of BMI, in type 2 diabetes.
MCP-1 is a potent chemotactic factor for
monocytes (23) and has been associated
with cardiovascular disease and diabetes
(16). In the Framingham cohort, MCP-1
was more strongly associated with VAT
thanwithSAT(11).Ourﬁndingsaresim-
ilar to the Framingham cohort, as we also
observed a strong correlation between
VAT and MCP-1 that was independent of
BMI. ICAM-1 and VCAM-1 are members
of the cellular adhesion molecule family
that have been implicated in inﬂamma-
tory and atherosclerotic processes (13).
Elevatedlevelsofbothhavebeenreported
in obesity (24). In the Framingham co-
hort, both SAT and VAT were associated
with ICAM-1 but neither of these rela-
tions persisted after adjustment for BMI
(11). In contrast, in our study, VAT was
associated with ICAM-1 before and after
adjustment for BMI. In contrast to ﬁnd-
ings in predominantly nondiabetic popu-
lations, we found no independent
relationships among BMI, VAT or SAT,
and ﬁbrinogen or MMP9 in fully adjusted
models (11,25).
Although prospective studies will be
necessary to determine the causal nature
of these associations, our results suggest
that in obese subjects with type 2 diabe-
tes, both BMI and VAT are important
drivers of systemic inﬂammation. While
BMI is strongly associated with CRP and
IL-6 levels, VAT is the primary determi-
nantofICAM,VCAM,MCP-1,andPAI-1.
ICAM and VCAM are found in the vessel
wall where their level of expression is re-
lated to atherosclerotic plaque remodel-
ing (13,17,18). MCP-1 and PAI-1 are
signiﬁcant markers of cardiovascular dis-
ease risk (14–16). Our ﬁndings indicate
that adipose tissue distribution remains
an important determinant of systemic in-
ﬂammation in type 2 diabetes. They un-
derscore the importance of managing
excessadiposity,includingthatinthevis-
ceral fat depot, for optimally managing
cardiovascularriskinsubjectswithtype2
diabetes.
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